Reply from authors re: Camillo Porta, Sergio Bracarda, Romano Danesi. Steroids in prostate cancer: the jury is still out... and even more confused. Eur Urol 2015;67:680-1: Corticosteroids in prostate cancer: known benefits versus potential risks.
作者信息
Parker Chris, De Bono Johann
机构信息
Royal Marsden Hospital, Sutton, UK.
Institute of Cancer Research, Sutton, UK.
出版信息
Eur Urol. 2015 Apr;67(4):681-2. doi: 10.1016/j.eururo.2014.11.042. Epub 2014 Nov 29.
PMID:25442054
Abstract
摘要
相似文献
1
Reply from authors re: Camillo Porta, Sergio Bracarda, Romano Danesi. Steroids in prostate cancer: the jury is still out... and even more confused. Eur Urol 2015;67:680-1: Corticosteroids in prostate cancer: known benefits versus potential risks.
Eur Urol. 2015 Apr;67(4):681-2. doi: 10.1016/j.eururo.2014.11.042. Epub 2014 Nov 29.
2
Steroids in prostate cancer: the jury is still out... and even more confused.
Eur Urol. 2015 Apr;67(4):680-1. doi: 10.1016/j.eururo.2014.11.002. Epub 2014 Nov 20.
3
Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer.
Cancer Biol Ther. 2015;16(2):207-9. doi: 10.1080/15384047.2014.1002687.
4
A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.
Eur Urol. 2015 Apr;67(4):673-9. doi: 10.1016/j.eururo.2014.10.004. Epub 2014 Oct 16.
5
Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
BJU Int. 2016 Dec;118(6):880-884. doi: 10.1111/bju.13483. Epub 2016 Apr 6.
6
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18.
7
Prolonged biochemical response after discontinuation of orteronel (TAK-700) in a patient with metastasized castration-resistant prostate cancer.
Acta Oncol. 2016 May;55(5):656-8. doi: 10.3109/0284186X.2015.1118657. Epub 2016 Apr 4.
8
Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
Clin Genitourin Cancer. 2014 Oct;12(5):e197-203. doi: 10.1016/j.clgc.2014.02.007. Epub 2014 Mar 2.
9
A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
Eur Urol. 2016 Jul;70(1):35-41. doi: 10.1016/j.eururo.2015.12.050. Epub 2016 Jan 15.
10
Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
Eur Urol. 2016 Dec;70(6):e170-e171. doi: 10.1016/j.eururo.2016.05.029. Epub 2016 May 27.
Zotero 插件